Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alexion Pharmaceuticals Inc. ALXN

Healthcare Biotechnology
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS... see more

Recent & Breaking News (NDAQ:ALXN)

Safirstein Metcalf LLP Announces That A Class Action Lawsuit Has Been Filed Against Alexion Pharmaceuticals, Inc. - ALXN

GlobeNewswire December 28, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alexion Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017

Business Wire December 27, 2016

SHAREHOLDER ALERT: Class Action Lawsuit Against Alexion Announced by Holzer & Holzer

Business Wire December 27, 2016

ALEXION (ALXN) ALERT: Johnson & Weaver, LLP Announces Filing of Class Action Complaint Against Alexion Pharmaceuticals, Inc.; Encourages all Investors to Contact the Firm for Information

PR Newswire December 23, 2016

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. – ALXN

GlobeNewswire December 22, 2016

Alexion's Drug Trial Miss Doesn't Change Analysts' Long-Term Thesis

Benzinga.com  December 22, 2016

Alexion Announces Top-Line Results from Phase 2/3 PROTECT Study of Eculizumab (Soliris®) for the Prevention of Delayed Graft Function (DGF) After Kidney Transplantation

Business Wire December 21, 2016

ALXN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Alexion Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of January 17, 2017

Business Wire December 21, 2016

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Alexion Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit – ALXN

GlobeNewswire December 20, 2016

Robbins Arroyo LLP Is Investigating the Officers and Directors of Alexion Pharmaceuticals, Inc. (ALXN) on Behalf of Shareholders

Business Wire December 16, 2016

ALXN LOSS ALERT: Rosen Law Firm Reminds Alexion Pharmaceuticals, Inc. Investors of Important Deadline in Class Action – ALXN

Business Wire December 15, 2016

Alexion Pharmaceuticals, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors

Business Wire December 13, 2016

15 Biggest Mid-Day Losers For Tuesday

Benzinga.com  December 13, 2016

The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Alexion Technologies Corporation Investors and Encourages Investors to Contact the Firm

Business Wire December 13, 2016

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline: January 17, 2017

GlobeNewswire December 13, 2016

Covered Call reports for Alexion Pharmaceuticals, Cornerstone OnDemand, Inc., Northrop Grumman Corporation, Opko Health and Lockheed Martin Corporation include trade ideas that offer returns of 23% or more!

PR Newswire December 13, 2016

ALEXION SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. – (ALXN)

Business Wire December 12, 2016

Mid-Afternoon Market Update: Achaogen Surges On Positive Phase 3 Results; Alexion Shares Slide

Benzinga.com  December 12, 2016

Mid-Day Market Update: Crude Oil Up Over 3%; Ophthotech Shares Tumble After Failed Phase 3 Trial Of Fovista

Benzinga.com  December 12, 2016

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Alexion Technologies Corporation Investors and Encourages Investors to Contact the Firm

Business Wire December 12, 2016